	US 12,465,636 B2
	Method of making afucosylated anti-FGFR2IIIB antibodies
Thomas Harding, San Francisco, CA (US); Kristen Pierce, Burlingame, CA (US); Namrata Patil, Sunnyvale, CA (US); Thomas Brennan, San Jose, CA (US); and Julie Hambleton, San Francisco, CA (US)
Assigned to Five Prime Therapeutics, Inc., Thousand Oaks, CA (US)
Filed by Five Prime Therapeutics, Inc., Thousand Oaks, CA (US)
Filed on Dec. 17, 2021, as Appl. No. 17/554,423.
Application 17/554,423 is a division of application No. 16/181,784, filed on Nov. 6, 2018, granted, now 11,235,059.
Application 16/181,784 is a division of application No. 15/166,798, filed on May 27, 2016, granted, now 10,172,937, issued on Jan. 8, 2019.
Application 15/166,798 is a division of application No. 14/447,751, filed on Jul. 31, 2014, abandoned.
Claims priority of provisional application 61/933,632, filed on Jan. 30, 2014.
Claims priority of provisional application 61/901,732, filed on Nov. 8, 2013.
Claims priority of provisional application 61/861,198, filed on Aug. 1, 2013.
Prior Publication US 2022/0168416 A1, Jun. 2, 2022
Int. Cl. A61K 39/395 (2006.01); A61K 31/337 (2006.01); A61K 31/513 (2006.01); A61K 33/243 (2019.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01)

CPC A61K 39/3955 (2013.01) [A61K 31/337 (2013.01); A61K 31/513 (2013.01); A61K 33/243 (2019.01); A61K 45/06 (2013.01); C07K 16/2863 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/41 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01)]

13 Claims

1. A method for making a composition comprising afucosylated anti-FGFR2IIIb antibodies, said method comprising:

culturing a host cell comprising a nucleic acid encoding an anti-FGFR2IIIb antibody comprising heavy chain and light chain variable regions under conditions suitable for expressing the nucleic acid and producing afucosylated anti-FGFR2IIIb antibodies;

wherein the heavy chain variable region comprises:

(i) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 6;

(ii) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 7; and

(iii) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 8;

and the light chain variable region comprises:

(iv) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 9;

(v) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 10; and

(vi) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 11,

wherein the host cell lacks a functional alpha-1,6-fucosyltransferase gene (FUT8) gene; and

recovering anti-FGFRIIIb antibodies produced by the host cell, wherein at least 95% of the recovered anti-FGFR2IIIb antibodies are afucosylated.